The phase 2 trial aimed to investigate the efficacy and safety of surufatinib combined with sintilimab as a potential 1L treatment for patients with advanced GC/GEJC. The primary endpoint was to determine ORR. Researchers noticed promising preliminary efficacy and manageable safety of surufatinib plus sintilimab as 2L treatment for advanced GC/GEJC patients; further […]...
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Advertisement
Background The combination of immune-checkpoint inhibitors and antiangiogenic agents can synergistically modulate the tumor microenvironment and represents a promising treatment option. Here, we evaluated the efficacy and safety of camrelizumab plus famitinib (a receptor tyrosine kinase …
Background Immune-related adverse events (irAEs) are major barriers of clinical management and further development of immune checkpoint inhibitors (ICIs) for cancer therapy. Therefore, biomarkers associated with the onset of severe irAEs are needed. In this study, …
Background Squamous non-small cell lung cancer (SQ-NSCLC) is the 2nd most common type of lung cancer. Given the paucity of actionable oncogene drivers, and lack of efficacy from multiple therapies in the Lung-MAP trial, there is …
